We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Co-Diagnostics, Inc.

Co-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-a... read more Featured Products: More products

Download Mobile App





Co-Diagnostics Showcases PCR Platform at WHX Labs Dubai

By LabMedica International staff writers
Posted on 10 Feb 2026

Co-Diagnostics, Inc. More...

(Co-Dx; Salt Lake City, UT, USA), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, is showcasing its transformative PCR platform at WHX Labs Dubai, taking place February 10–13, 2026.

Co-Dx's participation at the event follows the formation of its recently announced joint venture, CoMira Diagnostics, with Arabian Eagle Manufacturing in the Kingdom of Saudi Arabia. CoMira Diagnostics was formed to localize manufacturing and distribution of Co-Diagnostics' technologies and intellectual property across Saudi Arabia and 18 additional countries in the Middle East and North Africa ("MENA"). The event provides an opportunity for Co-Dx to engage with regional stakeholders and support its strategy to expand access to high-quality molecular diagnostics throughout the region, including the company's upcoming Co-Dx PCR platform, currently in clinical studies in the United States.

Attendees interested in learning more about the Co-Dx's products can visit Co-Dx and CoMira representatives at the World Trade Center Utah booth. World Trade Center Utah is a member of the World Trade Centers Association founded in 2006 with the goal of helping Utah companies increase revenue and create jobs by expanding international sales, attracting foreign investment, and facilitating international partnerships.

The Co-Dx PCR platform is a portable, real-time molecular diagnostics system designed to bridge the gap between high-quality laboratory testing and the convenience of at-home or point-of-care (PoC) settings. The platform aims to democratize access to "gold-standard" PCR technology by making it compact, affordable, and user-friendly. It delivers clinical-grade results in approximately 30 minutes, providing a rapid turnaround that eliminates the need for centralized laboratory processing. The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, all associated tests and licensed applications of the technology) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.

Related Links:
Co-Diagnostics, Inc.


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.